Neuratam800 mg

Neuratam is a cyclic GABA-derivative (pyrrolidone derivative) nootropic agent used for the following indications, classified by strength of evidence:

Established / Guideline-Supported Use

• Cortical myoclonus: Neuratam is well established as an adjunct treatment (used together with other antimyoclonic therapy) for cortical myoclonus of various origins in adults and children. This is the most robustly evidence-supported indication for Neuratam and is an approved indication in several countries.

Adjunct / Regionally-Approved Uses (Weaker Evidence)

• Vertigo and dizziness of vascular, traumatic, or other origin, as symptomatic adjunct therapy.
• Adjunct treatment of dyslexia in children (in combination with speech/language therapy), approved in some regional markets, though evidence is limited and inconsistent.
• Cognitive symptoms associated with cerebrovascular disease, aging, or brain injury, used as adjunct/symptomatic therapy in some markets; evidence for meaningful clinical benefit is limited.

Off-Label / Investigational Uses

• Adjunct management of acute vaso-occlusive sickle cell crisis (based on Neuratam's effect on red-cell deformability) — used off-label in some settings; not a standard of care.

Neuratam is not approved by the US FDA for any indication; it is marketed as a prescription medicine in Bangladesh, Europe, and various Asian markets for the indications above.

Piracetam is available in several dosage forms and strengths for oral and parenteral use, including:

• Tablets/film-coated tablets: 400 mg, 800 mg, and 1200 mg Piracetam
• Oral solution/syrup: commonly 333 mg/mL or an equivalent concentration of Piracetam
• Injection (IV/IM ampoule): commonly 1 g/5 mL or 3 g/15 mL Piracetam solution

Exact available strengths and forms vary by manufacturer; confirm the specific product's composition before dispensing.

Neuratam is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA) and is the prototype member of the pyrrolidone (racetam) class of nootropic agents. Unlike sedatives or psychostimulants, Neuratam is described as having no significant sedative, stimulant, or vasodilatory action of its own, but is thought to influence neuronal, vascular, and cognitive functions through effects on neuronal membrane fluidity, synaptic plasticity, and cerebral microcirculation.

Neuratam has been used clinically since the 1970s, mainly in Europe and Asia, and is not approved for marketing in the United States.

Neuratam belongs to the nootropic agents class, specifically the pyrrolidone (racetam) derivatives, a group of cyclic GABA analogues.

The precise mechanism of action of Piracetam is not fully established. Proposed mechanisms include:

• Modulation of AMPA-type glutamate receptors, enhancing neurotransmission and synaptic plasticity.
• Improvement of neuronal membrane fluidity, which may support neuronal signaling, particularly in aging or hypoxic states.
• Enhancement of the mitochondrial ATP/ADP ratio in neurons, supporting cellular energy metabolism under conditions of hypoxia.
• Effects on cerebral microcirculation, including reduced erythrocyte and platelet aggregation and improved red-cell deformability, which may improve microvascular blood flow.

Piracetam is well absorbed orally with an oral bioavailability close to 100%, does not undergo significant hepatic metabolism, and is eliminated almost entirely unchanged by renal excretion, with an elimination half-life of approximately 4-5 hours in adults with normal renal function.

Neuratam tablets and oral solution may be taken with or without food; taking with food may reduce the mild gastrointestinal upset some patients experience. Tablets should be swallowed with a glass of water and not crushed or chewed unless the product is specifically designed for that use. Neuratam injection is administered by slow intravenous or intramuscular route by a healthcare professional. Do not stop or change the dose of Neuratam without consulting the prescribing physician, particularly in myoclonus, where abrupt discontinuation may provoke rebound symptoms (see Precautions and Warnings).

Neuratam has the following clinically significant drug interactions:

• Thyroid hormones (T3/T4): Case reports describe confusion, irritability, and sleep disturbance when Neuratam is combined with thyroid hormone preparations; monitor for these symptoms if co-administered.
• Anticoagulants and antiplatelet agents (e.g., warfarin, aspirin, clopidogrel): Neuratam has mild antiplatelet activity and may theoretically add to bleeding risk when combined with these agents; use with caution and monitor for bleeding, especially before surgery or dental procedures.
• CNS stimulants: Concurrent use with other CNS-stimulating agents may increase the risk of nervousness, agitation, or insomnia due to additive stimulatory effects.

Inform the prescribing physician of all other medicines, supplements, and herbal products being used before starting Neuratam.

The most commonly reported adverse effects of Neuratam include:

• Nervousness and agitation
• Insomnia
• Weight gain
• Gastrointestinal upset (abdominal pain, diarrhea, nausea)

Less common effects include drowsiness, dizziness, headache, and in patients treated for myoclonus, dose-related hyperkinesia or ataxia. Rare effects include skin rash or hypersensitivity reactions. Contact your physician if any side effect is severe or persistent.

Neuratam crosses the placental barrier, and data on use in human pregnancy are limited. Neuratam should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use. Neuratam is excreted into breast milk; breastfeeding is generally not recommended during treatment with Neuratam unless considered essential by the treating physician, who should weigh the benefits of treatment against potential risk to the infant.

Use Neuratam with caution in the following situations:

• Renal impairment: Neuratam is eliminated almost entirely by the kidneys; dose reduction is required in renal impairment (see Use in Special Populations), and Neuratam is contraindicated in severe renal impairment (see Contraindications).
• Discontinuation in myoclonus: In patients being treated for cortical myoclonus, Neuratam should be discontinued gradually (by decrements of approximately 1.2 g every 2 days) rather than abruptly, since sudden withdrawal may provoke rebound seizures/myoclonus.
• Bleeding risk: Due to mild antiplatelet effects, use caution in patients with bleeding disorders, prior to surgery, or when combined with anticoagulant/antiplatelet drugs (see Interactions).
• Elderly patients: Dose adjustment based on renal function is often needed in elderly patients due to age-related decline in renal clearance.

Limited data are available on Neuratam overdose. Reported symptoms with very high doses include diarrhea, abdominal pain, and agitation. In case of suspected overdose of Neuratam, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic; since Neuratam is renally cleared, hemodialysis may be considered to enhance elimination in severe cases, particularly in patients with renal impairment.

Store Neuratam at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

For cortical myoclonus, Neuratam is typically continued long-term as part of ongoing antimyoclonic therapy, with periodic reassessment of dose and benefit by the treating physician. For vertigo or other adjunct indications, treatment with Neuratam is usually reassessed after approximately 8 weeks to determine whether continued therapy is beneficial. Duration should always be determined by the prescribing physician based on individual response.

Nootropic agents; Pyrrolidone (racetam) derivatives; Cyclic GABA derivatives

Piracetam's exact mechanism of action is not completely understood. It is believed to act by modulating neuronal AMPA-glutamate receptor function, enhancing neuronal membrane fluidity, and improving mitochondrial energy metabolism, without exerting classical sedative, stimulant, or vasodilator activity. Piracetam also reduces platelet and erythrocyte aggregation, which may improve microcirculatory blood flow. See Pharmacology for further detail.

The use of Neuratam in children is limited to specific, specialist-supervised indications. Neuratam may be used as adjunct therapy for cortical myoclonus in children, with weight-based dosing determined by the treating specialist. In some regional markets, Neuratam is also used as an adjunct in children aged 8 years and above with dyslexia, combined with educational/speech therapy. Safety and efficacy of Neuratam for general cognitive enhancement or other unapproved uses in children have not been established, and such use is not recommended.